文献速递慢性肾脏病血液净化与透析水电解质与酸碱

NaPi-IIb抑制剂DS-2330b治疗CKD血透患者高磷血症的1b期研究

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2020-12-23

这项1b期研究评估了口服NaPi-IIb抑制剂DS-2330b在CKD血透患者中的安全性和疗效。结果显示DS-2330b安全耐受但未显示临床意义的疗效。

要点

  • DS-2330b单药或联合sevelamer在血透患者中安全且耐受良好。
  • DS-2330b单药降血磷幅度与安慰剂相似,未显示临床意义疗效。
  • DS-2330b联合sevelamer或sevelamer联合安慰剂降血磷幅度最大。

核心结论

  • DS-2330b单药或联合sevelamer在血透患者中安全耐受,但未显示临床意义的疗效。

研究设计与样本

  • 2部分、随机、安慰剂和阳性对照、单次和多次给药的1b期研究,纳入CKD血透患者。
  • Part A评估DS-2330b 250 mg溶液和片剂的安全性和药代动力学,6例完成。
  • Part B随机分组:安慰剂每日三次、DS-2330b 400 mg每日三次、DS-2330b 400 mg联合sevelamer 1.6 g每日三次、sevelamer 1.6 g联合安慰剂每日三次,治疗14天。

主要发现

  • Part A中2例患者发生与DS-2330b无关的严重不良事件。
  • Part B中DS-2330b单药组血磷较基线平均变化为-2.2±1.5 mg/dl,安慰剂组为-1.9±1.1 mg/dl。
  • DS-2330b联合sevelamer组和sevelamer联合安慰剂组血磷较基线下降幅度最大。
  • 9例(28.1%)患者发生至少1次治疗中出现的不良事件(TEAE),7例发生药物相关TEAE。
  • DS-2330b组与对照组TEAE发生率相当。

临床怎么用

  • DS-2330b单药或联合sevelamer在血透患者中安全耐受,但降血磷疗效未达临床意义,暂不支持临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) has a prevalence of 9.1% globally, and frequently results in elevated serum phosphate, increasing cardiovascular morbidity and mortality risk in hemodialysis (HD) patients. DS-2330b, an oral NaPi-IIb inhibitor, reduced intestinal phosphate absorption in preclinical studies, but its effect in patients with CKD is unknown. This 2-part, randomized, placebo- and active-controlled, single- and repeated-dose, phase 1b study evaluated safety and efficacy of DS-2330b in patients with CKD on HD. METHODS: Part A, a 2-period, 2-way study, evaluated safety and pharmacokinetics of DS-2330b 250 mg in solution and tablet formulations. Part B assessed the safety of DS-2330b in solution (chosen based on results of part A) and its effect on serum phosphate. Patients were randomized to placebo 3 times daily (TID), DS-2330b 400 mg TID, DS-2330b 400 mg with sevelamer 1.6 g TID, and sevelamer 1.6 g with placebo TID for 14 days. Safety endpoints included adverse event (AE) monitoring. RESULTS: Six patients completed part A. Two patients experienced serious AEs considered unrelated to DS-2330b treatment. Thirty-two patients enrolled and completed part B. Serum phosphate mean change from baseline ± SD was -2.2±1.5 mg/dl versus -1.9 ± 1.1 mg/dl for DS-2330b monotherapy versus placebo. Patients receiving DS-2330b with sevelamer or sevelamer with placebo experienced the greatest serum phosphate decrease from baseline. Nine patients (28.1%) experienced ≥1 treatment-emergent AE (TEAE); 7 patients experienced drug-related TEAEs. The TEAE incidence was comparable between DS-2330b and control groups. CONCLUSIONS: DS-2330b, alone or in combination with sevelamer, was safe and well tolerated but did not demonstrate clinically meaningful efficacy in HD patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Maruyama S, Marbury TC, Connaire J, et al. NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients. Kidney Int Rep. 2020. PMID: 33732982. doi:10.1016/j.ekir.2020.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。